Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

Howes, 2015, Glutamate and dopamine in schizophrenia: an update for the 21st century, J Psychopharmacol, 29, 97, 10.1177/0269881114563634

Poels, 2014, Imaging glutamate in schizophrenia: review of findings and implications for drug discovery, Mol Psychiatry, 19, 20, 10.1038/mp.2013.136

Hietala, 1995, Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients, Lancet, 346, 1130, 10.1016/S0140-6736(95)91801-9

Demjaha, 2012, Dopamine synthesis capacity in patients with treatment-resistant schizophrenia, Am J Psychiatry, 169, 1203, 10.1176/appi.ajp.2012.12010144

Howes, 2009, The dopamine hypothesis of schizophrenia: version III–the final common pathway, Schizophr Bull, 35, 549, 10.1093/schbul/sbp006

Laruelle, 1996, Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects, Proc Natl Acad Sci U S A, 93, 9235, 10.1073/pnas.93.17.9235

Seeman, 1975, Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons, Science, 188, 1217, 10.1126/science.1145194

Fusar-Poli, 2015, Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials, Schizophr Bull, 41, 892, 10.1093/schbul/sbu170

Miyamoto, 2012, Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents, Mol Psychiatry, 17, 1206, 10.1038/mp.2012.47

Lindenmayer, 2000, Treatment refractory schizophrenia, Psychiatr Q, 71, 373, 10.1023/A:1004640408501

Suzuki, 2011, Treatment resistant schizophrenia and response to antipsychotics: a review, Schizophr Res, 133, 54, 10.1016/j.schres.2011.09.016

Adler, 1999, Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia, Am J Psychiatry, 156, 1646, 10.1176/ajp.156.10.1646

Krystal, 2005, Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function, Arch Gen Psychiatry, 62, 985, 10.1001/archpsyc.62.9.985

Krystal, 2000, Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions, Biol Psychiatry, 47, 137, 10.1016/S0006-3223(99)00097-9

Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch Gen Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004

Lahti, 2001, Effects of ketamine in normal and schizophrenic volunteers, Neuropsychopharmacology, 25, 455, 10.1016/S0893-133X(01)00243-3

Malhotra, 1996, NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers, Neuropsychopharmacology, 14, 301, 10.1016/0893-133X(95)00137-3

Lahti, 1995, Ketamine activates psychosis and alters limbic blood flow in schizophrenia, Neuroreport, 6, 869, 10.1097/00001756-199504190-00011

Lahti, 1995, Subanesthetic doses of ketamine stimulate psychosis in schizophrenia, Neuropsychopharmacology, 13, 9, 10.1016/0893-133X(94)00131-I

Olney, 1995, Glutamate receptor dysfunction and schizophrenia, Arch Gen Psychiatry, 52, 998, 10.1001/archpsyc.1995.03950240016004

Rowland, 2005, Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study, Am J Psychiatry, 162, 394, 10.1176/appi.ajp.162.2.394

Stone, 2012, Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology, Mol Psychiatry, 17, 664, 10.1038/mp.2011.171

Bartha, 1997, Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy, Arch Gen Psychiatry, 54, 959, 10.1001/archpsyc.1997.01830220085012

de la Fuente-Sandoval, 2011, Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis, Neuropsychopharmacology, 36, 1781, 10.1038/npp.2011.65

Kegeles, 2012, Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy, Arch Gen Psychiatry, 69, 449, 10.1001/archgenpsychiatry.2011.1519

Kraguljac, 2013, Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia, JAMA Psychiatry, 70, 1294, 10.1001/jamapsychiatry.2013.2437

Plitman, 2016, Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with first-episode psychosis: a proton magnetic resonance spectroscopy study with implications for glial dysfunction, Schizophr Bull, 42, 415, 10.1093/schbul/sbv118

Théberge, 2002, Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers, Am J Psychiatry, 159, 1944, 10.1176/appi.ajp.159.11.1944

Leklem, 1971, Quantitative aspects of tryptophan metabolism in humans and other species: a review, Am J Clin Nutr, 24, 659, 10.1093/ajcn/24.6.659

Dounay, 2015, Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway, J Med Chem, 58, 8762, 10.1021/acs.jmedchem.5b00461

Schwarcz, 2012, Kynurenines in the mammalian brain: when physiology meets pathology, Nat Rev Neurosci, 13, 465, 10.1038/nrn3257

Vécsei, 2013, Kynurenines in the CNS: recent advances and new questions, Nat Rev Drug Discov, 12, 64, 10.1038/nrd3793

Fukui, 1991, Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism, J Neurochem, 56, 2007, 10.1111/j.1471-4159.1991.tb03460.x

Gál, 1980, L-kynurenine: its synthesis and possible regulatory function in brain, Neurochem Res, 5, 223, 10.1007/BF00964611

Guillemin, 2001, Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection, J Neurochem, 78, 842, 10.1046/j.1471-4159.2001.00498.x

Guidetti, 2007, Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain, J Neurochem, 102, 103, 10.1111/j.1471-4159.2007.04556.x

Perkins, 1982, An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid, Brain Res, 247, 184, 10.1016/0006-8993(82)91048-4

Birch, 1988, Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor, Eur J Pharmacol, 154, 85, 10.1016/0014-2999(88)90367-6

Kessler, 1989, A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists, J Neurochem, 52, 1319, 10.1111/j.1471-4159.1989.tb01881.x

Hilmas, 2001, The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications, J Neurosci, 21, 7463, 10.1523/JNEUROSCI.21-19-07463.2001

Pocivavsek, 2016, Chapter 25 - Astrocytes as pharmacological targets in the treatment of schizophrenia: focus on kynurenic acid, Handbook of Behavioral Neuroscience, 423

Wang, 2006, Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35, J Biol Chem, 281, 22021, 10.1074/jbc.M603503200

DiNatale, 2010, Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling, Toxicol Sci, 115, 89, 10.1093/toxsci/kfq024

Lugo-Huitrón, 2011, On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress, Neurotoxicol Teratol, 33, 538, 10.1016/j.ntt.2011.07.002

Foster, 1984, Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid, Neurosci Lett, 48, 273, 10.1016/0304-3940(84)90050-8

Erhardt, 2007, The kynurenic acid hypothesis of schizophrenia, Physiol Behav, 92, 203, 10.1016/j.physbeh.2007.05.025

Myint, 2012, Kynurenines: from the perspective of major psychiatric disorders, FEBS J, 279, 1375, 10.1111/j.1742-4658.2012.08551.x

Wonodi, 2010, Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia, Schizophr Bull, 36, 211, 10.1093/schbul/sbq002

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, J Clin Epidemiol, 62, 1006, 10.1016/j.jclinepi.2009.06.005

Erhardt, 2009, Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders, CNS Drugs, 23, 91, 10.2165/00023210-200923020-00001

Müller, 2011, Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects, Curr Pharm Des, 17, 130, 10.2174/138161211795049552

Schwarcz, 2016, Kynurenines and glutamate: multiple links and therapeutic implications, Adv Pharmacol, 76, 13, 10.1016/bs.apha.2016.01.005

Stone, 2013, The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders, Br J Pharmacol, 169, 1211, 10.1111/bph.12230

Stone, 2013, An expanding range of targets for kynurenine metabolites of tryptophan, Trends Pharmacol Sci, 34, 136, 10.1016/j.tips.2012.09.006

Iwata, 2015, Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials, Mol Psychiatry, 20, 1151, 10.1038/mp.2015.68

DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Duval, 2000, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics, 56, 455, 10.1111/j.0006-341X.2000.00455.x

Kim, 2013, Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity, J Clin Epidemiol, 66, 408, 10.1016/j.jclinepi.2012.09.016

Barry, 2009, Kynurenine pathway in psychosis: evidence of increased tryptophan degradation, J Psychopharmacol, 23, 287, 10.1177/0269881108089583

Chiappelli, 2014, Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance, JAMA Psychiatry, 71, 761, 10.1001/jamapsychiatry.2014.243

Fazio, 2015, Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia, Sci Rep, 5, 17799, 10.1038/srep17799

Fukushima, 2014, Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients, PLoS One, 9, e101652, 10.1371/journal.pone.0101652

Kegel, 2014, Imbalanced kynurenine pathway in schizophrenia, Int J Tryptophan Res, 7, 15, 10.4137/IJTR.S16800

Linderholm, 2012, Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia, Schizophr Bull, 38, 426, 10.1093/schbul/sbq086

Miller, 2006, Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder, Brain Res, 1073-1074, 25, 10.1016/j.brainres.2005.12.056

Myint, 2011, Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients, Brain Behav Immun, 25, 1576, 10.1016/j.bbi.2011.05.005

Nilsson, 2005, Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia, Schizophr Res, 80, 315, 10.1016/j.schres.2005.07.013

Ravikumar, 2000, Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders, Neurol India, 48, 231

Sathyasaikumar, 2011, Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia, Schizophr Bull, 37, 1147, 10.1093/schbul/sbq112

Schwarcz, 2001, Increased cortical kynurenate content in schizophrenia, Biol Psychiatry, 50, 521, 10.1016/S0006-3223(01)01078-2

Schwieler, 2015, Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway, J Psychiatry Neurosci, 40, 126, 10.1503/jpn.140126

Erhardt, 2001, Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia, Neurosci Lett, 313, 96, 10.1016/S0304-3940(01)02242-X

Muller, 2006, Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission, Neurotox Res, 10, 131, 10.1007/BF03033242

Ceresoli-Borroni, 2006, Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain, J Neural Transm (Vienna), 113, 1355, 10.1007/s00702-005-0432-z

Nilsson, 2007, Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors, J Psychiatr Res, 41, 144, 10.1016/j.jpsychires.2005.12.001

Kirkpatrick, 2013, Inflammation and schizophrenia, Schizophr Bull, 39, 1174, 10.1093/schbul/sbt141

Tourjman, 2013, Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis, Schizophr Res, 151, 43, 10.1016/j.schres.2013.10.011

Upthegrove, 2014, Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis, Schizophr Res, 155, 101, 10.1016/j.schres.2014.03.005

Müller, 2015, The role of inflammation in schizophrenia, Front Neurosci, 9, 372, 10.3389/fnins.2015.00372

Steiner, 2012, Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity, World J Biol Psychiatry, 13, 482, 10.3109/15622975.2011.583941

Miller, 2004, Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia, Neurobiol Dis, 15, 618, 10.1016/j.nbd.2003.12.015

Wonodi, 2011, Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes, Arch Gen Psychiatry, 68, 665, 10.1001/archgenpsychiatry.2011.71

Holtze, 2012, Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls, J Psychiatry Neurosci, 37, 53, 10.1503/jpn.100175

Lavebratt, 2014, The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression, Mol Psychiatry, 19, 334, 10.1038/mp.2013.11

Giorgini, 2013, Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain, J Biol Chem, 288, 36554, 10.1074/jbc.M113.503813

Rassoulpour, 2005, Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum, J Neurochem, 93, 762, 10.1111/j.1471-4159.2005.03134.x

Röver, 1997, Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase, J Med Chem, 40, 4378, 10.1021/jm970467t

Speciale, 1996, (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats, Eur J Pharmacol, 315, 263, 10.1016/S0014-2999(96)00613-9

Rothermundt, 2009, S100B in schizophrenia: an update, Gen Physiol Biophys, 28 Spec No Focus, F76

Wonodi, 2014, Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia, Schizophr Res, 160, 80, 10.1016/j.schres.2014.10.026

Erhardt, 2004, Endogenous kynurenic acid disrupts prepulse inhibition, Biol Psychiatry, 56, 255, 10.1016/j.biopsych.2004.06.006

Nilsson, 2006, Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons, J Neural Transm (Vienna), 113, 557, 10.1007/s00702-005-0343-z

Shepard, 2003, Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat, Neuropsychopharmacology, 28, 1454, 10.1038/sj.npp.1300188

Chess, 2006, Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding, Behav Brain Res, 170, 326, 10.1016/j.bbr.2006.03.006

Chess, 2007, Elevations of endogenous kynurenic acid produce spatial working memory deficits, Schizophr Bull, 33, 797, 10.1093/schbul/sbl033

Chess, 2009, L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning, Behav Brain Res, 201, 325, 10.1016/j.bbr.2009.03.013

Pocivavsek, 2014, Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats, Psychopharmacology (Berl), 231, 2799, 10.1007/s00213-014-3452-2

Pocivavsek, 2012, Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood, Eur J Neurosci, 35, 1605, 10.1111/j.1460-9568.2012.08064.x

Pocivavsek, 2011, Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory, Neuropsychopharmacology, 36, 2357, 10.1038/npp.2011.127

Alexander, 2013, Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine, Neuroscience, 238, 19, 10.1016/j.neuroscience.2013.01.063

Alexander, 2012, Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine, Psychopharmacology (Berl), 220, 627, 10.1007/s00213-011-2539-2

Pershing, 2015, Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia, Neuropharmacology, 90, 33, 10.1016/j.neuropharm.2014.10.017

Olsson, 2012, Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice, J Neural Transm (Vienna), 119, 155, 10.1007/s00702-011-0706-6

Potter, 2010, Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior, Neuropsychopharmacology, 35, 1734, 10.1038/npp.2010.39

Kozak, 2014, Reduction of brain kynurenic acid improves cognitive function, J Neurosci, 34, 10592, 10.1523/JNEUROSCI.1107-14.2014

Nilsson-Todd, 2007, Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites, Acta Neuropsychiatr, 19, 45, 10.1111/j.1601-5215.2006.00170.x

Beggiato, 2013, Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo, Eur J Neurosci, 37, 1470, 10.1111/ejn.12160

Carpenedo, 2001, Presynaptic kynurenate-sensitive receptors inhibit glutamate release, Eur J Neurosci, 13, 2141, 10.1046/j.0953-816x.2001.01592.x

Konradsson-Geuken, 2010, Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry, Neuroscience, 169, 1848, 10.1016/j.neuroscience.2010.05.052

Konradsson-Geuken, 2009, Second-by-second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats, Synapse, 63, 1069, 10.1002/syn.20693

Wu, 2010, The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex, J Mol Neurosci, 40, 204, 10.1007/s12031-009-9235-2

Lopes, 2007, Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors, J Pharmacol Exp Ther, 322, 48, 10.1124/jpet.107.123109

Wu, 2007, Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?, J Neural Transm (Vienna), 114, 33, 10.1007/s00702-006-0562-y

Amori, 2009, Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum, Neuroscience, 159, 196, 10.1016/j.neuroscience.2008.11.055

Erhardt, 2002, Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid, Acta Physiol Scand, 175, 45, 10.1046/j.1365-201X.2002.00962.x

Erhardt, 2001, Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons, Amino Acids, 20, 353, 10.1007/s007260170032

Linderholm, 2007, Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis, Neuropharmacology, 53, 918, 10.1016/j.neuropharm.2007.09.003

Schwieler, 2006, Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons–possible involvement of endogenous kynurenic acid, Synapse, 59, 290, 10.1002/syn.20241

Schwieler, 2008, Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area, Life Sci, 83, 170, 10.1016/j.lfs.2008.05.014

Liu, 2014, Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment–role of brain kynurenic acid, Brain Behav Immun, 36, 80, 10.1016/j.bbi.2013.10.010

Olsson, 2009, Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia, Int J Neuropsychopharmacol, 12, 501, 10.1017/S1461145708009383

Schwieler, 2003, Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid, Neuropsychopharmacology, 28, 1770, 10.1038/sj.npp.1300255

Zmarowski, 2009, Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release, Eur J Neurosci, 29, 529, 10.1111/j.1460-9568.2008.06594.x

Beggiato, 2014, Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex, Neuropharmacology, 82, 11, 10.1016/j.neuropharm.2014.02.019

Amori, 2009, On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo, J Neurochem, 109, 316, 10.1111/j.1471-4159.2009.05893.x

Pellicciari, 2006, Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor, ChemMedChem, 1, 528, 10.1002/cmdc.200500095

Wu, 2014, Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor, Schizophr Bull, 40, S152, 10.1093/schbul/sbt157

Choi, 2013, Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy, Br J Psychiatry, 203, 172, 10.1192/bjp.bp.111.107359

Conley, 2009, The effects of galantamine on psychopathology in chronic stable schizophrenia, Clin Neuropharmacol, 32, 69, 10.1097/WNF.0b013e31816f2795

Lindenmayer, 2011, Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia, Schizophr Res, 125, 267, 10.1016/j.schres.2010.08.021

Ball, 2014, Tryptophan-catabolizing enzymes - party of three, Front Immunol, 5, 485, 10.3389/fimmu.2014.00485

Fatokun, 2013, Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease, Amino Acids, 45, 1319, 10.1007/s00726-013-1602-1

Miller, 2009, The evolution of schizophrenia: a model for selection by infection, with a focus on NAD, Curr Pharm Des, 15, 100, 10.2174/138161209787185805

Yu, 2016, TDO as a therapeutic target in brain diseases, Metab Brain Dis, 31, 737, 10.1007/s11011-016-9824-z

Schwieler, 2005, Prostaglandin-mediated control of rat brain kynurenic acid synthesis--opposite actions by COX-1 and COX-2 isoforms, J Neural Transm (Vienna), 112, 863, 10.1007/s00702-004-0231-y

Müller, 2008, Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development, Expert Opin Ther Targets, 12, 1497, 10.1517/14728220802507852

Akhondzadeh, 2007, Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial, Schizophr Res, 90, 179, 10.1016/j.schres.2006.11.016

Rappard F Müller N . Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia. Neuropsychopharmacology. 2004;29:S222.

Golightly, 2001, Acute tryptophan depletion in schizophrenia, Psychol Med, 31, 75, 10.1017/S0033291799003062

Hitsman, 2005, Effects of acute tryptophan depletion on negative symptoms and smoking topography in nicotine-dependent schizophrenics and nonpsychiatric controls, Neuropsychopharmacology, 30, 640, 10.1038/sj.npp.1300651

Sharma, 1997, Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms, Neuropsychobiology, 35, 5, 10.1159/000119323

Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261

Green, 2004, Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria, Biol Psychiatry, 56, 301, 10.1016/j.biopsych.2004.06.023